Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
16.68
+0.65 (4.05%)
At close: Jun 26, 2026, 4:00 PM EDT
16.61
-0.07 (-0.42%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$175,310
Profits / Employee
-$1,046,674
Market Cap
2.33B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Ocular Therapeutix | 325 |
| Biohaven | 274 |
| Immunome | 206 |
| Kodiak Sciences | 130 |
| Aurinia Pharmaceuticals | 128 |
NTLA News
- 9 days ago - Intellia Therapeutics rises 12.9% - TheFly
- 9 days ago - Intellia Therapeutics rises 10.7% - TheFly
- 12 days ago - Intellia Therapeutics presents additional results from Phase 3 HAELO trial - TheFly
- 13 days ago - Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 17 days ago - Intellia Therapeutics Transcript: AGM 2026 - Transcripts
- 21 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 - GlobeNewsWire